126 related articles for article (PubMed ID: 25525858)
1. Genetic and molecular targets in lymphoma: implications for prognosis and treatment.
Bachegowda LS; Barta SK
Future Oncol; 2014 Dec; 10(15):2509-28. PubMed ID: 25525858
[TBL] [Abstract][Full Text] [Related]
2. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targeting in lymphoma.
Booth S; Collins G
Br J Haematol; 2021 Jan; 192(1):50-61. PubMed ID: 32609383
[TBL] [Abstract][Full Text] [Related]
4. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
5. Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
Arita A; McFarland DC; Myklebust JH; Parekh S; Petersen B; Gabrilove J; Brody JD
Future Oncol; 2013 Oct; 9(10):1549-71. PubMed ID: 24106904
[TBL] [Abstract][Full Text] [Related]
6. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
[TBL] [Abstract][Full Text] [Related]
7. Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
Iida S
Oncology; 2015; 89 Suppl 1():4-6. PubMed ID: 26551834
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
9. [Molecular target drugs for malignant lymphoma].
Terui Y
Nihon Rinsho; 2010 Oct; 68(10):1881-8. PubMed ID: 20954334
[TBL] [Abstract][Full Text] [Related]
10. Lymphomas: its gene expression profiling.
Tiwari M
J Cancer Res Ther; 2011; 7(4):393-8. PubMed ID: 22269398
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic targets in melanoma.
Martí RM; Sorolla A; Yeramian A
Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
[TBL] [Abstract][Full Text] [Related]
12. Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
O'Connor OA
J Clin Oncol; 2005 Sep; 23(26):6429-36. PubMed ID: 16155030
[TBL] [Abstract][Full Text] [Related]
13. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies.
Rossi D; Ciardullo C; Gaidano G
Semin Cancer Biol; 2013 Dec; 23(6):422-30. PubMed ID: 23665546
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Newton HB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):355-78. PubMed ID: 15877531
[TBL] [Abstract][Full Text] [Related]
16. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
17. New drugs for aggressive B-cell and T-cell lymphomas.
Murawski N; Pfreundschuh M
Lancet Oncol; 2010 Nov; 11(11):1074-85. PubMed ID: 21051020
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.
Nagel D; Vincendeau M; Eitelhuber AC; Krappmann D
Oncogene; 2014 Dec; 33(50):5655-65. PubMed ID: 24469030
[TBL] [Abstract][Full Text] [Related]
19. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
Sawas A; Diefenbach C; O'Connor OA
Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
